Welcome in CFDB (Cystic Fibrosis DataBase)!
This is a web-based, free access tool for health care professionals, researchers and students to evaluate in real time what are the current evidences about clinical efficacy of interventions in CF.
You'll find more than 1,300 studies divided in 8 sections, including Cochrane reviews, Cochrane protocols, DARE, HTA and Economic reviews, published RCT, published non-RCT, congress abstracts and ongoing trials.
Objective of CFDB (Cystic Fibrosis DataBase)
CFDB is a database and was ideated to classify clinical studies to get answers to specific questions:
- which interventions are effective, in which groups of CF patients and for which outcomes?
- to what extent do the results of the literature allow to make decisions for specific clinical issues? What issues need to be studied further?
This tool may help clinicians, researchers, students to have a faster updated view of clinical research in CF by using queries on the main topics in CF care. It could also be helpful to anyone going to design new studies, as it provides a concise description of what is currently known and what issues, on the contrast, need additional research.
Latest articles
Prebiotics for people with cystic fibrosis
Cochrane Database of Systematic Reviews - Cochrane Review
Details- 2023
- Williams N
Digital technology for delivering and monitoring exercise programs for people with cystic fibrosis
Cochrane Database of Systematic Reviews - Cochrane Review
Details- 2023
- Pereira NP
Randomized Trial of the Insulin-Only iLet Bionic Pancreas for the Treatment of Cystic Fibrosis- Related Diabetes.
primary studies published RCT
Details- 2023
- Sherwood JS
Embedded Specialist Palliative Care in Cystic Fibrosis: Results of a Randomized Feasibility Clinical Trial.
primary studies published RCT
Details- 2023
- Kavalieratos D
Improvement in Lung Clearance Index and Chest CT Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Study.
primary studies published, non RCT
Details- 2023
- McNally P
Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes.
primary studies published, non RCT
Details- 2023
- Grancini V
A Phase 3, Open-label, and Rollover Study to Evaluate the Long-term Safety and Tolerability of Lumacaftor/Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation
ongoing trials trial from other registries
Details- 2023